Class I · High risk
Promacta (eltrombopag)
Cross Contamination with Other Products: product is being recalled due to possible cross-contamination with peanut flour.
FDA Drug Recalls
18,003 recalls, newest first
Class III · Low risk
QUIK-CARE Aerosol Foam Hand Sanitizer
Incorrect/undeclared excipients: Hand sanitizer was made using the wrong alcohol raw material.
Class II · Moderate risk
Anastrozole Tablets
GMP Deviations: Potential cross contamination due to cleaning procedure failure.
Class II · Moderate risk
Anastrozole Tablets
GMP Deviations: Potential cross contamination due to cleaning procedure failure.
Class II · Moderate risk
MethylPREDNISolone Tablets
CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.
Class II · Moderate risk
Pramipexole Dihydrochloride Tablets 1.5 mg 90-count bottle
CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.
Class II · Moderate risk
MethylPREDNISolone Tablets
CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.
Class II · Moderate risk
MethylPREDNISolone Tablets
CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.
Class II · Moderate risk
MethylPREDNISolone Tablets
CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.
Class II · Moderate risk
MethylPREDNISolone Tablets
CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.
Class II · Moderate risk
Pramipexole Dihydrochloride Tablets 1 mg
CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.
Class II · Moderate risk
Pramipexole Dihydrochloride Tablets 0.5 mg
CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.
Class II · Moderate risk
Pramipexole Dihydrochloride Tablets 0.25 mg
CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.
Class II · Moderate risk
Pramipexole Dihydrochoride Tablets 0.25 mg
CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.
Class II · Moderate risk
Pramipexole DihydrochlorideTablets 0.125 mg
CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.
Class II · Moderate risk
Pramipexole Dihydrochloride Tablets 0.125 mg
CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.
Class II · Moderate risk
Anastrozole Tablets
CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.
Class II · Moderate risk
ANASTROZOLE Tablets
CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.
Class II · Moderate risk
Senna (sennosides 8.8 mg)
Failed Impurities/Degradation Specifications: Atypical odor and unpleasant taste was reported
Class II · Moderate risk
Senna (sennosides 8.8 mg)
Failed Impurities/Degradation Specifications: Atypical odor and unpleasant taste was reported
Class I · High risk
The Beast
Marketed without an Approved NDA/ANDA: The Beast contains undeclared sildenafil which was discovered through FDA analysis.
Class II · Moderate risk
Bevacizumab 2.5 mg/0.1 mL
Lack of assurance of sterility
Class II · Moderate risk
Losartan Potassium Tablets USP 25 mg 90 film coated tablets Rx…
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer
Class II · Moderate risk
Losartan Potassium Tablets USP 100 mg 1000 film coated tablets Rx…
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer
Class II · Moderate risk
Losartan Potassium Tablets USP 50 mg 90 film coated tablets…
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer